Acadia Pharmaceuticals | ACAD - Debt


Acadia Pharmaceuticals reported $73.85M in Debt for its fiscal quarter ending in June of 2026.





Debt Change Date
Acadia Pharmaceuticals USD 73.85M 23.06M Jun/2026
ALKERMES USD 1.57B 10.58M Sep/2026
Alnylam Pharmaceuticals USD 2.48B 1.21B Sep/2026
Biogen USD 7.69B 398.3M Sep/2026
BioMarin Pharmaceutical USD 4.19B 11.99M Sep/2026
Bristol-Myers Squibb USD 42.88B 2.18B Sep/2026
Cara Therapeutics USD 0 0 Mar/2025
Corcept Therapeutics USD 8.99M 430K Sep/2026
Cytokinetics USD 1.27B 18.17M Jun/2026
Eisai JPY 186.08B 50.58B Mar/2026
Eli Lilly USD 54.91B 11.54B Jun/2026
Incyte USD 38.27M 1.16M Jun/2026
J&J USD 49.04B 5.95B Jun/2026
Moderna USD 1.29B 11M Jun/2026
Neurocrine Biosciences USD 392.3M 9.5M Sep/2026
Pfizer USD 62.67B 523M Sep/2026
Prothena USD 6.99M 663K Jun/2026
PTC Therapeutics USD 2.84B 2.15B Sep/2026
Sarepta Therapeutics USD 857.36M 188.48M Sep/2026
Ultragenyx Pharmaceutical USD 36M 2.17M Dec/2025
Vanda Pharmaceuticals USD 4.96M 4.96M Dec/2024
Vertex Pharmaceuticals USD 6.48B 4.5B Sep/2026